Rebif® (interferon beta-1a) is a disease modifying drug (DMD) used to treat relapsing forms of multiple sclerosis (MS). It is identical to the interferon beta protein produced by the human body. Rebif has been approved for the treatment of relapsing forms of MS in over 80 countries worldwide. It is the leading treatment for relapsing MS outside the U.S. and is the fastest-growing treatment on the U.S. market.

A new formulation of Rebif® with improved tolerability has recently
been approved in the EU and Canada and is under regulatory review
in other countries including the US.

 Interferon beta helps to coordinate the immune system in its fight against infection. It also helps to regulate inflammation. Inflammation in the brain and spinal cord is the major cause of MS manifestations. Inflammation starts very early in the disease and results in the destruction of the nerve covering (myelin) and the nerve fiber itself. Once the nerve fiber is destroyed, it is lost forever.

That is why interferon beta therapy should be started as early as possible in the disease. Dose and frequency of injections are important for the clinical efficacy of Rebif®.

Rebif® is available at a dose of 22 mcg, three times per week for the gradual stepping up of dosing to 44 mcg and for patients who are unable to tolerate the full treatment benefit of Rebif® 44 mcg doses.

Rebif® is currently the only interferon beta treatment that is available worldwide in ready-to-use, prefilled syringes.